Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients

100Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Alms: To measure pimecrolimus blood concentrations and to evaluate tolerabllity and efficacy in children and infants treated topically for atopic dermatitis with pimecrolimus cream 1% for three weeks. Methods: Three open label, non-controlled, multiple topical dose studies were conducted in children aged 8-14 years (study A, ten patients), and in infants aged 8-30 months (study B, eight patients) and 4-11 months (study C, eight patients). Pimecrolimus blood concentrations were determined on days 4 and 22 of treatment, and at end of study. Efficacy was assessed using the Eczema Area and Severity Index (EASI). Results: Pimecrolimus blood concentrations were consistently low, typicolly (81%) below 1 ng/ml, with more than half of the measurements below the assay limit of quantitation (0.5 ng/ml) in studies A and B. The highest blood concentration measured throughout the three studies was 2.6 ng/ml. The cream was well tolerated, locally and systemically. The most common adverse event suspected to be related to study medication was a transient mild to moderate stinging sensation at the application site in 5/26 patients. There was no indication of any systemic adverse effect. The patients responded well to therapy with a rapid onset of action, usually within four days. Median reductions of EASI from baseline at day 22 were 55% (study A), 63% (study B), and 83% (study C). Conclusion: Three weeks treatment of children and infants with extensive atopic dermatitis, using pimecrolimus cream 1% twice daily, is well tolerated and results in minimal systemic exposure, at which no systemic effect is expected.

References Powered by Scopus

The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis

980Citations
N/AReaders
Get full text

Worldwide variations in the prevalence of symptoms of atopic eczema in the international study of asthma and allergies in childhood

882Citations
N/AReaders
Get full text

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.

351Citations
N/AReaders
Get full text

Cited by Powered by Scopus

A systematic review of the safety of topical therapies for atopic dermatitis

166Citations
N/AReaders
Get full text

Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis

133Citations
N/AReaders
Get full text

Topical calcineurin inhibitors and lymphoma risk: Evidence update with implications for daily practice

118Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Allen, B. R., Lakhanpaul, M., Morris, A., Lateo, S., Davies, T., Scott, G., … Stephenson, T. J. (2003). Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Archives of Disease in Childhood, 88(11), 969–973. https://doi.org/10.1136/adc.88.11.969

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

50%

Professor / Associate Prof. 2

25%

Researcher 2

25%

Readers' Discipline

Tooltip

Medicine and Dentistry 10

63%

Agricultural and Biological Sciences 3

19%

Chemistry 2

13%

Nursing and Health Professions 1

6%

Article Metrics

Tooltip
Mentions
References: 1

Save time finding and organizing research with Mendeley

Sign up for free